A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
A Multi-part, Phase 1, First-Time-in-Human Study to Investigate Safety, Tolerability, and PK of VH4770359 in Healthy Participants
ViiV Healthcare
214 participants
May 14, 2026
INTERVENTIONAL
Conditions
Summary
VH4770359 (also known as GSK4770359) is an antiretroviral compound. This first-in-human study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered VH4770359 in healthy participants. The findings from this study will support the design of future clinical studies of VH4770359 in people living with HIV.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive the assigned dose formulation of VH4770359 orally.
Participants will receive placebo to match the VH4770359 dose formulation.
Participants receive 2 mg Midazolam on Days -1, Day 1 and Day 14.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07525544